Imago BioSciences, Inc.

Imago BioSciences, Inc. (IMGO) priced its initial public offering on Jul 16, 2021 at $16.00 per share, raising $134.4M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $513.9M. Jefferies was lead-left underwriter, joined by TD Cowen, Stifel and Guggenheim. Latham & Watkins advised the company and O’Melveny & Myers advised the underwriters.

Imago BioSciences, Inc. is a clinical-stage biopharmaceutical company developing small molecules that target the enzyme LSD1, which plays a central role in blood cell production. Its lead candidate, bomedemstat, is for myeloproliferative neoplasms, including myelofibrosis, essential thrombocythemia and polycythemia vera.

Status

IPO

Ticker

IMGO

Exchange

Nasdaq Global Select

Priced

Jul 16, 2021

IPO price

$16.00

Raised

$134.4M

Market cap at IPO price

$513.9M

First filed

Jun 25, 2021

Underwriters

Jefferies, TD Cowen, Stifel and Guggenheim

Company counsel

Latham & Watkins

Underwriters' counsel

O’Melveny & Myers

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.